DPP4 is highly expressed in the liver, while the expression and serum levels of DPP-4 are elevated in steatohepatitis patients, and also correlate with hepatic steatosis, fibrosis, and hepatocyte apoptosis [203, 204], making DPP4i an attractive therapeutic option for patients with NAFLD. The gene discussed is DPP4; the disease is fatty liver disease.